Dapagliflozin Reduces CV Risk in Heart Failure with Preserved LVEF – Consumer Health News

MONDAY, Aug. 29, 2022 (HealthDay News) — For heart failure patients with mildly reduced or preserved ejection fraction, the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the combined risk of worsening heart failure or cardiovascular death, according to a study published online August 27 in the New England Journal of Medicine to coincide with the European Society of Cardiology Congress 2022, to be held August 26-29 in Barcelona, ​​Spain.

Scott D. Solomon, MD, of Brigham and Women’s Hospital, Boston, and colleagues randomly assigned 6,263 patients with heart failure and a left ventricular ejection fraction over 40% to receive either dapagliflozin, or a corresponding placebo, in addition to the usual treatment. The primary outcome, assessed in a time-to-event analysis, was a composite of worsening heart failure or cardiovascular death.

The researchers found that the primary outcome occurred in 16.4% of 3131 patients in the dapagliflozin group and 19.5% of 3132 patients in the placebo group (relative risk, 0.82; 95% confidence interval %, 0.73 to 0.92; P

“These data provide additional evidence to support the use of an SGLT2 inhibitor as a lifeline treatment in patients with heart failure, regardless of the presence or absence of type 2 diabetes mellitus or diabetes mellitus. left ventricular ejection fraction,” the authors write.

The study was funded by AstraZeneca, the maker of dapagliflozin.

Abstract/Full text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More information

Comments are closed.